Valeritas Holdings, Inc. Announces Publication of Study Results Reflecting Real-World Clinical Practice
January 18, 2017 at 08:00 am
Share
Valeritas Holdings, Inc. announced the publication of study results reflecting real-world clinical practice showing that nursing home residents with type 2 diabetes who used the V-Go® Insulin Delivery device had improved glycemic control compared to residents who received insulin via traditional injections with syringes or pens. Use of V-Go was also associated with reduced nursing staff time and labor costs for insulin administration. The study was published in the January 2017 print issue of the Journal of Gerontological Nursing (43(1): 10-16). The study was a retrospective chart review of patients with type 2 diabetes who resided in a single nursing home and who were receiving basal and bolus insulin via syringes or pens (standard of care or SOC) to manage blood glucose levels. Patients were included in the V-Go group if they had used V-Go during a six-month timeframe. V-Go patients were matched to SOC patients based on their mean 30-day blood glucose (BG) measures at baseline. The primary endpoint was the proportion of BG time in the range of 100 mg/dL to 200 mg/dL, which reflected the target glycemic range of older adults with complex health status. Secondary endpoints included mean daily BG measurements, glycemic fluctuations and excursions and the number of daily injection sites.
Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.